stockmarketproxy
/
INCYNasdaqSEC EDGAREDGAR

INCYTE CORP

Services-Commercial Physical & Biological Research·WILMINGTON, DE·FY end 12/31·CIK 879169
OverviewFinancialsCompensationGovernanceInsidersFilings

Financials

5-year history · USD
MetricFY 2025FY 2024FY 2023FY 2022FY 2021Trend
Revenue$5.1B$4.2B$3.7B$3.4B$3.0B
Gross Profit——————
Operating Income$1.5B$61.4M$620.5M$579.4M$585.8M
Net Income$1.3B$32.6M$597.6M$340.7M$948.6M
Operating CF$1.4B$335.3M$496.5M$969.9M$749.5M
Capex—$48.7M————
Free Cash Flow—$286.6M————
Buybacks$0$2.0B———
Dividends——————
Gross Margin——————
Operating Margin29.5%1.4%16.8%17.1%19.6%
Net Margin25.0%0.8%16.2%10.0%31.8%
FCF Margin—6.8%————
R&D / Revenue39.9%61.5%44.0%46.7%48.8%
Effective Tax22.7%89.7%28.4%35.6%-66.3%
Debt / Equity——————
Buybacks / FCF—699.4%————

Peer comparison

Services-Commercial Physical & Biological Research · 1 peer
CEO Pay Ratio
INCY
47:1
CRL
251:1
CEO total comp
INCY
—
CRL
—
Net Margin
INCY
25.0%
CRL
-3.6%